Kidney shield drug fails early test in heart surgery patients

NCT ID NCT05524051

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tested a single dose of TIN816, given as an IV infusion, to see if it could prevent acute kidney injury in adults after cardiac surgery. The trial enrolled 102 patients aged 45 and older who were at risk for kidney damage. However, the study was terminated early, so we don't have complete data on whether TIN816 is safe or effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TIN816
What this could lead to: If it worked, TIN816 could help prevent kidney damage after heart surgery, reducing the need for dialysis.
What could go wrong: This trial was terminated early, so results are limited. It was a small phase 2 study, and the drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY FOLLOWING CARDIAC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY FOLLOWING CARDIAC SURGERY

Contacts and locations

Show contact details

Locations

Duke Univ Medical Center

Durham, North Carolina, 27710, United States
Mayo Clinic Phoenix

Phoenix, Arizona, 85054, United States
Novartis Investigative Site

CABA, Buenos Aires, C1118AAT, Argentina
Novartis Investigative Site

Buenos Aires, C1428DCO, Argentina
Novartis Investigative Site

CABA, C1181ACH, Argentina
Novartis Investigative Site

Genk, Limburg, 3600, Belgium
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Salvador, Estado de Bahia, 40323-010, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 05403 000, Brazil
Novartis Investigative Site

Montreal, Quebec, H1T 1C8, Canada
Novartis Investigative Site

Montreal, Quebec, H2X 0A9, Canada
Novartis Investigative Site

Montreal, Quebec, H4J 1C5, Canada
Novartis Investigative Site

Québec, Quebec, GIV 4G5, Canada
Novartis Investigative Site

Ostrava, Poruba, 708 52, Czechia
Novartis Investigative Site

Tartu, Estonia, 50406, Estonia
Novartis Investigative Site

Nantes, 44093, France
Novartis Investigative Site

Neuilly-sur-Seine, 92200, France
Novartis Investigative Site

Paris, 75013, France
Novartis Investigative Site

Poitiers, 86021, France
Novartis Investigative Site

Rennes, 35033, France
Novartis Investigative Site

Regensburg, Bavaria, 93053, Germany
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Leipzig, Saxony, 04289, Germany
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Pécs, Baranya, 7623, Hungary
Novartis Investigative Site

Debrecen, Hajdu Bihar Megye, 4032, Hungary
Novartis Investigative Site

Budapest, H 1096, Hungary
Novartis Investigative Site

Budapest, H-1083, Hungary
Novartis Investigative Site

Ahmedabad, Gujarat, 380054, India
Novartis Investigative Site

Lucknow, Uttar Pradesh, 226003, India
Novartis Investigative Site

Vilnius, LT-08406, Lithuania
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

Badalona, Barcelona, 08916, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08907, Spain
Novartis Investigative Site

Madrid, 28006, Spain
Novartis Investigative Site

Taipei, 10002, Taiwan